Docetaxel versus docetaxel plus cisplatin for non-small-cell lung cancer: a meta-analysis of randomized clinical trials

// Ang Li 1, * , Zhi-jian Wei 1, * , Han Ding 1 , Hao-shuai Tang 1 , Heng-xing Zhou 1 , Xue Yao 1 and Shi-Qing Feng 1 1 Department of Orthopedics, Tianjin Medical University General Hospital, Heping District, Tianjin, China * These authors have contributed equally to this work Correspondence to: Shi-Qing Feng, email: sqfeng@tmu.edu.cn Keywords: docetaxel, cisplatin, meta-analysis, non-small-cell lung cancer, response rate Received: July 02, 2016     Accepted: November 16, 2016     Published: April 13, 2017 ABSTRACT Objective: To compare the activity, efficacy and toxicity of docetaxel versus docetaxel plus cisplatin in patients with non-small-cell lung cancer. Methods: A literature search was performed in the EMBASE, Medline, Cochrane Library, Web of Science, China National Knowledge Internet, Wan-fang databases. The trials that were found were then evaluated for eligibility. The Cochrane Collaboration’s Review Manager software was used to perform the meta-analyses. Results: Nine clinical trials including 1257 patients were included. The docetaxel plus cisplatin regimens had higher overall response rates compared with the docetaxel regimen (RR = 0.70; 95% CI, 0.61 to 0.80; P < 0.00001). No statistically significant difference was observed between the two regimens with respect to the one-year survival rate (RR = 1.04; 95% CI, 0.90 to 1.19; P = 0.62). Patients treated with the DP regimen were more likely to experience anemia, thrombocytopenia, nausea/vomiting, nephrotoxicity, hyponatremia, mucositis and treatment-related deaths compared with patients treated with docetaxel alone. No significant difference was observed between the two regimens with respect to the occurrence of neurotoxicity, diarrhea, fatigue, pneumonitis, neutropenia and leucopenia. Conclusions: The docetaxel plus cisplatin combination regimen resulted in a high response rate and a high adverse effect rate compared with docetaxel monochemotherapy for non-small-cell lung cancer.